# A Study of AK129 in Patients With Advanced Malignant Tumors

> **NCT05645276** · PHASE1 · RECRUITING · sponsor: **Akeso** · enrollment: 182 (estimated)

## Conditions studied

- Advanced Malignant Tumors(Stage IA-IB)

## Interventions

- **DRUG:** AK129 IV infusion

## Key facts

- **NCT ID:** NCT05645276
- **Lead sponsor:** Akeso
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-02
- **Primary completion:** 2026-02
- **Final completion:** 2026-06
- **Target enrollment:** 182 (ESTIMATED)
- **Last updated:** 2025-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05645276

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05645276, "A Study of AK129 in Patients With Advanced Malignant Tumors". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05645276. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*